vTv Therapeutics
VTVT
23 hedge funds and large institutions have $23.1M invested in vTv Therapeutics in 2025 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 8 increasing their positions, 3 reducing their positions, and 1 closing their positions.
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
167% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 3
164% more capital invested
Capital invested by funds: $8.74M → $23.1M (+$14.3M)
15.33% more ownership
Funds ownership: 22.43% → 37.76% (+15%)
10% more funds holding
Funds holding: 21 → 23 (+2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SB
Samsara BioCapital
Palo Alto,
California
|
+$2.94M |
| 2 |
SL
Siren LLC
Greenwich,
Connecticut
|
+$2.86M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
+$895K |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$258K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$66.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$37K |
| 2 |
Northern Trust
Chicago,
Illinois
|
-$21.3K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$193 |
| 4 |
Raymond James Financial
St Petersburg,
Florida
|
-$15 |
VTVT Hedge Fund Activity: Q3 2025 in Review
23 of the 7,641 institutional investors tracked by Wall St. Rank reported a position in vTv Therapeutics (VTVT) for Q3 2025, worth a combined $23.1M — up 164% from $8.74M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new VTVT positions and 1 closed out — a net gain of 2 holders — while 8 added to existing stakes and 3 trimmed.
The largest buyer was Samsara BioCapital, adding an estimated $2.94M. The largest seller was Millennium Management, cutting an estimated $37K.
- 23 institutional investors held vTv Therapeutics (VTVT) as of Q3 2025, up from 21 in Q2 2025.
- Funds reported $23.1M of vTv Therapeutics stock for Q3 2025, up 164% quarter-over-quarter.
- 3 funds opened new vTv Therapeutics positions in Q3 2025 and 1 closed out, a net change of +2 holders.
- The largest vTv Therapeutics buyer in Q3 2025 was Samsara BioCapital, an estimated $2.94M added.
- The largest vTv Therapeutics seller in Q3 2025 was Millennium Management, an estimated $37K sold.
Based on aggregated 13F filings for Q3 2025.